Expression microarrays identified a novel transcript, designated as Ugene, whose expression is absent in normal colon and colon adenomas, but that is commonly induced in malignant colon cancers. These findings were validated by real-time PCR
Introduction
Cancers of the colon and rectum (CRC) are the second leading cause of cancer deaths among adult Americans. Colon cancer develops as a result of the progressive accumulation of genetic and epigenetic alterations in key oncogenes and tumor suppressor genes that lead to the transformation of normal colonic epithelium to adenocarcinoma (1) . In addition to primary genetic alterations, the cancer phenotype is also importantly modulated by downstream alterations in the levels of expression of different effector genes (2) (3) (4) . Expression microarrays enable comprehensive profiling of the cancer transcriptome and identification of cancerspecific changes in gene expression (5, 6) .
In this study, using a global gene expression profiling array, we identified a previously uncharacterized gene, called Ugene, which is overexpressed in malignant colon cancers. We further show that Ugene is frequently elevated in most malignant tumor types. In addition, we provide experimental evidence showing that Ugene protein is localized within the nucleus and forms a complex with uracil DNA glycosylase 2 (UNG2), a base excision repair (BER) enzyme.
Materials and Methods
Cell lines and tissues. VACO cell lines were established and maintained as previously described (7) . DLD1 and SW480 cell lines were obtained from the American Type Culture Collection. Normal colons, primary colon cancers, and liver metastasis tissues were obtained from the archives of University Hospitals of Cleveland under an institutional review boardapproved protocol. Total RNA and genomic DNA were prepared as described (8) .
DNA expression microarray analysis. As described previously (9), we designed custom expression monitoring microarrays using Affymetrix GeneChip technology (10) . Preparation of samples, hybridization to GeneChip expression microarrays, and data analysis were all performed as described previously (9) .
Rapid amplification of cDNA ends PCR. 5 ¶ and 3 ¶ Rapid amplification of cDNA ends (RACE)-ready cDNAs were generated from 2 Ag of total RNA (V241 cell line) using the 5 ¶/3 ¶ RACE kit (Roche). The gene-specific primers used for 5 ¶ RACE were as follows: SP1, 5 ¶-GCGGGACCTAGAG-CTTTTCT-3 ¶; SP2, 5 ¶-GAGGCAGGTGGAGTTTGAAG-3 ¶; and SP3, 5 ¶-ATCCC-TTCCCCAGCATTAAG-3 ¶. The gene-specific primer for 3 RACE was 5 ¶-ACC-TCATCCTTCCTGCGACG-3 ¶. Full-length Ugene was PCR amplified from RACE-ready cDNA using the forward 5 ¶-CCGACTGAGCCTCTAAAGCGAC-3 ¶ and reverse 5 ¶-TCCTGATTCACAAACTCTTGCTCC-3 ¶ primers.
Northern blot analysis. Northern blot analysis was performed as previously described (11) using the entire Ugene coding region as the probe.
Southern blot analysis. Total genomic DNA from cell lines and normal tissues were digested with PstI, separated by electrophoresis on a 0.8% agarose gel, and transferred onto a Zeta-Probe blotting membrane. 32 P-labeled DNA probes were prepared by random primer extension of a fragment containing the Ugene coding sequence. Equal loading of DNA was confirmed by rehybridizing blots with a probe designated to the TGFb-RII gene, which is relatively copy number invariant in CRC.
Human cancer dot blots. Radioactively labeled cDNA probes were synthesized from human Ugene or ubiquitin control cDNA using random primer labeling followed by probe purification on CHROMA SPIN + STE-100 columns (BD Biosciences). Hybridization of the cancer profiling array with human Ugene probes and washings of the array were done according to the manufacturer's recommendations (BD Biosciences). The hybridized cancer profiling arrays were then exposed to the phosphorimaging screens and scanned with a Storm 840 PhosphorImager. We then stripped this same membrane and hybridized it with human ubiquitin cDNA probe to show equal sample loading.
Ugene real-time PCR. Primers and a fluorogenic hybridization probe were designed using the Primer3 software (12) . Ugene was amplified using 400 nmol/L of forward primer 5 ¶-CTGTCTTCTTTCCTGCAACAAC-3 ¶ and reverse primer 5 ¶-TAGGACGTTTACACCTGTGGAG-3 ¶ and detected using fluorogenic hybridization probe 5 ¶-/56-FAM/ATAAACTGCCTGGCTGT-GAAACATCCAG/3BHQ_2/-3 ¶. h-2-Microglobulin (B2M) was amplified using 0.2Â of the human B2M TaqMan primer/probe kit (Perkin-Elmer Biosciences). Each PCR was carried out in triplicate in a 25-AL volume using TaqMan Assay Mastermix (Applied Biosystems) for 8 min at 95jC, followed by 50 cycles of 95jC for 15 s, 57jC for 30 s, and 72jC for 30 s. The level of Ugene expression was determined as the ratio of Ugene: B2M = 2 (CT B2M-CT Ugene)
. Construction of expression/deletion vectors. The coding sequence of Ugene (Ugene-p/Ugene-q, XM_001133365) and UNG2 (NM_080911) was PCR amplified and cloned into the eukaryotic expression vector pcDNA3.1/ V5/His-TOPO (Invitrogen) to generate COOH-terminal V5-tagged Ugene/ UNG2 expression vectors. The primer sequences for constructing the vectors are as follows: for Ugene, forward 5 ¶-ACCTCATCCTTCCTGCGACG-3 ¶ and reverse 5 ¶-TCTAATACACTCCTCTGCTGAGAT-3 ¶; for UNG2, forward 5 ¶-ATGGGCGTCTTCTGCCTTG-3 ¶ and reverse 5 ¶-CAGCTCCTTCCAGT-CAATG-3 ¶. FLAG-tagged constructs were similarly made by adding the complimentary FLAG tag sequence with a stop codon (5 ¶-TTACTTGT-CATCGTCGTCCTTGTAGTC-3 ¶) at the 5 ¶ end of the reverse primer. UNG2 deletion constructs were generated by blunt ligation of the PCR products, amplified using V5-tagged UNG2 expression vector as a template, with the primer sets as listed in Supplementary Table S1 . The decoy fusion protein 1-25-UNG2-green fluorescence protein (GFP) expression vector was constructed by ligating the following three fragments: (a) GFP DNA [PCR amplified from pEGFP-N1 template (Clontech) using forward 5 ¶-TTGAATT-CATGGTGAGCAAGGGCGAGGAG-3 ¶ and reverse 5 ¶-TTCTCGAGCCCTTG-TACAGCTCGTCCATGC-3 ¶, and digested with EcoRI and Xho I]; (b) nucleotides corresponding to 1 to 25 amino acids of UNG2 (amplified using forward 5 ¶-TTGGATCCCTCCTCAGCTCCAGGATGAT-3 ¶ and reverse 5 ¶-TTGAATTCCTCGGGGCTGGGGGCGTGT-3 ¶, then digested with BamH1 and EcoRI); (c) pcDNA4/myc-His(B) (Invitrogen) fragment (obtained by digesting the vector with BamHI and XhoI). In this construct, 1-25-UNG2-GFP is driven by a cytomegalovirus promoter with two copies of the TetO2 operator sequence, which can be suppressed by the Tet repressor.
Construction of DLD1 clones conditionally expressing 1-25-UNG2-GFP. DLD1 cells were seeded at 1.0 Â 10 6 /100-mm dish and transfected the next day with 1.6 Ag of pcDNA6/TR and 0.4 Ag pcDNA4/myc-His/1-25-UNG2-GFP plasmid using 12 AL of Fugene 6 (Roche Applied Sciences) as per the manufacturer's protocols, then selected by blasticidin (10 Ag/mL) and zeocin (200 Ag/mL) for 2 wk to derive clones conditionally expressing 1-25-UNG2-GFP fusion protein under doxycycline (0.5 Ag/mL) regulation.
Immunofluorescence. SW480 cells were seeded at 1.0 Â 10 6 /100-mm dish and transfected the next day with 2 Ag of V5-tagged Ugene expression vector using 12 AL of Fugene 6 (Roche Applied Sciences) as per the manufacturer's protocols. Immunofluorescence was performed 48 h after transfection using V5 antibody (Invitrogen) at 1:200, followed by Alexa Fluor 488 goat anti-mouse IgG antibody (Invitrogen) at 1:400.
Immunoprecipitation and Western blot analysis. HEK 293T cells were seeded at 4.0 Â 10 6 /T75 flask and transfected the next day with a total of 6 Ag plasmids using 36 AL of LipofectAMINE (Invitrogen). Cell lysates were prepared 48 h after transfection using the lysis buffer [50 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EDTA (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100] supplemented with the protease inhibitor mixture (Roche Applied Sciences). FLAG immunoprecipitation was performed with anti-FLAG M2 affinity gel as described in the manufacturer's protocol. After elution by either FLAG peptide (Sigma) or 3Â FLAG peptide (Sigma), eluates were used for biochemical activity assay or for Western blot. Western blots were performed using anti-FLAG M2 (Sigma, 1:1,000), anti-V5 (1:1,000, Invitrogen), anti-UNG (1:500, Abcam), anti-GFP (1:5,000, Invitrogen), or anti-h-actin (1:100,000, Sigma) antibodies, followed by horseradish peroxidase-conjugated donkey anti-mouse secondary antibody (1:1,500; Jackson ImmunoResearch Laboratories) and visualized by using an Enhanced Chemiluminescence Plus detection kit (Amersham Biosciences).
Somatic cell knockout. Somatic cell knockout was performed as described (13) . Knockout of both UNG1 and UNG2 transcription units was accomplished by disrupting the UNG locus exon 2 using left and right targeting arms amplified with the following primers: left arm, 5 ¶-GGCTCGAGAGGCACAAAGCGAATGAAAG-3 ¶, 5 ¶-CCGAATTCAGTCAGT-CACTCTGGATCCGGTCCAACT-3 ¶; right arm 5 ¶-GGACTAGTGGAGA-GAGCTGGAAGAAGCA-3 ¶, 5 ¶-AACCGCGGTTTGAACTTCACCACCACCA-3 ¶. UNG1-specific knockout was accomplished by eliminating the UNG1-specific exon 1 using targeting arms amplified with the following primers: left arm 5 ¶-GGCTCGAGAAGAGCCTGTCCAAAGAGCA-3 ¶/5 ¶-CCGAATTCCGGGAATTGGGAATTAGGTT-3 ¶; right arm 5 ¶-GGACTAGTCT-CTTGAGCCGCCTCTGC-3 ¶/5 ¶-AACCGCGGTTTGAACTTCACCACCACCA-3 ¶. Cells expressing only UNG2 were generated by UNG1-specific knockout of one allele combined with the UNG locus knockout of the second allele.
Endogenous Ugene epitope tagging. 3Â FLAG tagging of the endogenous Ugene-p gene was performed by somatic cell knock-in vectors, as described by Zhang and colleagues (14) . The primers used were as follows: left arm 5 ¶-GGCTCGAGCAACCTGGCCCTAAAGTTCA-3 ¶, 5 ¶-CCGA-TATCTCTAATACACTCCTCTGCTGAG-3 ¶ and right arm 5 ¶-GGACTAGTATG-GAATTATGATATATATGATATAC-3 ¶, 5 ¶-AACCGCGGCAAAACCACAA-CTCAGTCTGCT-3 ¶. Small interfering RNA-mediated Ugene silencing. The Ugene-specific and control small interfering RNAs (siRNA) were synthesized by Dharmacon. For siRNA transfection experiments, DLD1 cells were seeded on 100-mm culture dishes and transfected with 30 AL of 20 Amol/L siRNA stock using 30 AL LipofectAMINE 2000 (Invitrogen). Cell lysates were collected 48 h after transfection and knockdown was validated by Western blot. The sequences of Ugene siRNA-1017 were as follows: sense 5 ¶-GGAAGAUGCUAUUUCACCAUU-3 ¶, antisense 5 ¶-pUGGUGAAAUAGCAU-CUUCCUU-3 ¶.
In vitro UNG biochemical activity assay. The uracil-containing oligonucleotide (5 ¶-CCTGCCCTGUGCAGCTGTGGG-3 ¶; R&D Systems) was annealed to an equimolar amount of its complementary strand (5 ¶-CCCACAGCTGCACAGGGCAGG-3 ¶ or 5 ¶-CCCACAGCTGCGCAGGGCAGG-3 ¶ for U-A and U-G pairs, respectively), mixed and heated to 95jC in annealing buffer [20 mmol/L Tris-HCl (pH 8.0), 1 mmol/L EDTA, 1 mmol/L DTT, and 0.1 mg/mL bovine serum albumin], and allowed to slowly cool to room temperature. The DNA was then end labeled with g 32 P-dATP by T4 polynucleotide kinase. In vitro UNG biochemical activity assay was performed as per manufacturer's instruction (R&D Systems). In brief, after exposure to UNG2, which deglycosylates uracil, the deglycosylated oligonucleotide was split in half by incubation in alkali buffer (300 mmol/L NaOH, 97% formamide) at 100jC for 10 min.
Results
Identification of a novel gene, Ugene, overexpressed in most cancer types. To identify genes potentially involved in colon tumorigenesis, we used GeneChip gene expression microarrays to compare patterns of gene expression in RNA samples extracted from colon cancers versus normal colon epithelium. One transcript, an expressed sequence tag (EST) corresponding to Genbank accession number U46258, was noted to be of particular interest. Specifically, the detectable expression of this transcript was absent in 21 normal colonic mucosal samples (median value 25, corresponding to null expression), but was well detected in 39 malignant colon tumors (median value 125), 43 colon cancer hepatic metastases (median value 107), and 36 colon cancer cell lines (median value 220; Fig. 1A ). Ugene induction was found to be specific to colon cancer and was absent in nine precursor colon adenoma cases (median value 25, corresponding to null expression).
U46258 corresponds to a 123-bp EST sequence mapping to chromosome 1q32. To derive a full-length transcript corresponding to this EST, we identified by a BLAST search all ESTs in the dbEST database that mapped to within 20 kb of U46258. Connection reverse transcription-PCR from colon cancer cell lines (SW480 and VACO241) was used to identify ESTs linked to U46258. The 5 ¶ and 3 ¶ RACE PCR methods were used to complete the derivation of a colonic transcript that corresponded to U46258 and that contained the complete coding region of a novel gene. This gene, named Ugene, has an mRNA consisting of four exons. The open-reading frame encodes a 149-amino-acid protein (16.9 kDa) with an ATG start codon in exon 1 and a tumor-associated antigen (TAA) stop codon in exon 4 (Fig. 2) . Searching online databases did not identify any known protein motifs contained within the Ugene sequence. BLAST alignment results indicated that the Ugene mRNA sequence shared 99% identity to a predicted human mRNA (accession number XM_001133365), designated as ''Homo sapiens similar to family with sequence similarity 72, member A, '' which was computationally predicted from the Ugene locus (National Center for Biotechnology Information contig NT_086602) by the Gnomon gene prediction method.
To further characterize the Ugene transcript, we sequenced five or more individually cloned Ugene cDNAs from each of nine colon cancer cell lines. Surprisingly, each line showed two distinct Ugene transcripts, designated as Ugene-p and Ugene-q, which differed at three individual nucleotide positions in exons 1, 3, and 4, respectively. Two of the three nucleotide differences result in amino acid changes at codon 99 (Gly/Arg) and codon 125 (Trp/Arg; Fig. 2 ). These findings are suggestive that Ugene-p and Ugene-q arise from separate gene loci. In support of this interpretation, we additionally showed amplification from genomic DNA of both Ugene-p-and Ugene-q-specific forms of exons 3 and 4.
BLAST analysis showed 100% correct alignment of the four Ugene-p exons to two different positions on chromosome 1 (corresponding to Genbank accession numbers NT_086586 and NT_086602), suggesting either misassembly of chromosome 1 or multiple copies of this gene. Additionally, BLAST alignment identified two exons corresponding to Ugene-q exons 3 and 4 as located on chromosome 1, but at position different from Ugene-p (corresponding to Genbank accession number NT_034403). Our cDNA cloning supports that, in fact, four distinct Ugene-q exons exist, likely all located on chromosome 1. Because Ugene-p is conserved across all mammalian species, we focused on Ugene-p in this study.
As shown in Supplementary Fig. S1 , Northern blot analysis corroborated that Ugene transcripts are expressed by malignant but not normal colon tissues, detecting a single 2.4-kb Ugene mRNA with moderate to strong intensity in 10 of 11 colon cancer cell lines, but in none of four normal colon epithelial tissue samples. To provide a more quantitative measurement of Ugene induction, we extended this analysis by using real-time PCR. Realtime PCR showed only barely detectable Ugene expression in 11 of 11 normal colon epithelial samples (mean value 2.6, range 1.1-4.7), whereas colon cancer cell lines showed an average of 56-fold increased level of expression (mean value 147, range 3.3-503), with 11 of 13 colon cancer cell lines showing a >15-fold increase in expression (Fig. 1B) . To determine expression of Ugene-p-versus Ugene-q-encoded transcripts, we sequenced individual Ugene cDNA clones from two colon cancer cell lines, SW480 and VACO241. We found that in both cell lines, Ugene-p represents 60% of Ugene expression, whereas Ugene-q represents 40% (data not shown).
Overexpression of Ugene in malignant colon cancer was also confirmed by real-time PCR analysis of Ugene mRNA in primary colon cancers versus matched normal colon mucosa from the same individuals. A median increase of 6.8-fold in Ugene expression was observed in cancers versus matched colon normals, with >2-fold increase exhibited by 18 of the 20 tumors (Fig. 1C) . These 20 colon cancers examined by real-time PCR constituted a ''validation set'' of samples completely independent of those that had been previously characterized on the GeneChip expression microarrays.
Southern blotting of 12 colon cancer cell lines did not show any increase in Ugene gene copy number as an explanation for Ugene overexpression (data not shown).
To examine whether Ugene might be overexpressed in other cancer types, we probed a cDNA Cancer Profiling Array (BD Biosciences), comparing Ugene expression level in matched tumor and normal tissue from a variety of organs. As expected, a high proportion of colon cancer samples were observed to have elevated expression of Ugene (Fig. 1D) . Using densitometry, the intensity of the radioactive probe signal from each cDNA sample was quantitated. Twenty-two of 34 colon cancer cases (65%) showed >2-fold increased expression of Ugene. Furthermore, we also found Ugene expression elevated in multiple other common cancer types, including breast (56% of cases), lung (52% of cases), stomach (64% of cases), uterus (67% of cases), and ovary (79% of cases).
Ugene encodes a nuclear protein.
To investigate the subcellular localization of Ugene-encoded protein, a construct expressing V5 epitope-tagged Ugene-p protein was transfected into SW480 cells. Figure 3 shows the immunofluorescent staining for the V5 tag (green) in Ugene-transfected cells. Results show that tagged Ugene protein accumulates in nuclei, which were defined by 4 ¶,6-diamidino-2-phenylindole (DAPI) staining (red). As Ugene is a small protein (16.9 kDa) and lacks a nuclear localization signal, this accumulation suggested that Ugene might be held in the nucleus by interacting with other nuclear proteins.
Ugene binds to UNG2, a base excision DNA repair protein. To look for a potential Ugene partner, we performed a pull-down assay using FLAG-tagged Ugene-p protein overexpressed in SW480 cells. Using mass spectrometry, a protein band that precipitated in the Ugene-p pull down was identified as UNG2 (data not shown), an enzyme that is involved in BER by catalysis of uracil excision from DNA and is constitutively located in the nucleus (15, 16) .
To confirm the interaction of Ugene-p and UNG2, we first cotransfected tagged Ugene-p and UNG2 constructs, followed by immunoprecipitation of either protein, and then performed Western blot analysis of the immunoprecipitates to detect the presence of potential partners. We found Ugene-p and UNG2 coimmunoprecipitated together in assays in which either of the proteins was first pulled down (Fig. 4A) .
To prove that this binding of Ugene-p and UNG2 was not an artificial result due to protein overexpression, we tagged the endogenous Ugene-p locus in DLD1 cells by somatic cell knock-in of a 3Â FLAG epitope at exon 4, corresponding to the COOH terminus of the protein ( Fig. 4B; ref. 14) . We then coimmunoprecipitated Ugene-p with antibodies against the FLAG epitope. Western blot analysis confirmed that endogenous UNG2 coimmunoprecipitated with the tagged endogenous Ugene-p protein (Fig. 4C) . PCR analysis showed no change in total Ugene transcript expression in cells bearing the 3Â FLAG knock-in epitope and also showed the knock-in Ugene allele to be expressed at essentially the same level as the nontargeted alleles ( Supplementary Fig. S4 ).
Ugene-p binds to the NH 2 terminus of UNG2. To determine the UNG2 motif responsible for binding to Ugene-p, we made a series of constructs expressing V5 epitope-tagged nested UNG2 deletions (Fig. 5A) . After cotransfecting each of these V5 epitopetagged UNG2 deletion constructs with FLAG epitope-tagged Ugene-p, we immunoprecipitated Ugene-p and performed Western blot analysis to test for coimmunoprecipitation of each of the UNG2 deletion constructs (Fig. 5B) . One UNG2 deletion that lacked only sequences between codons 3 and 33 showed complete loss of the capacity to bind to Ugene-p. This result suggested that Ugene-p binds to the NH 2 terminus of UNG2.
To further test if the UNG2 NH 2 terminus is able to bind to Ugenep, we artificially synthesized peptides encoding the NH 2 -terminal amino acids 1 to 25 of UNG2 (1-25-UNG2). We then tested if this peptide could competitively block the binding of endogenous UNG2 to FLAG epitope-tagged endogenous Ugene-p. Figure 5C shows that adding the 1-25-UNG2 peptide into cell lysates blocked UNG2 binding to Ugene-p in a dose-dependent fashion. 1-25-UNG2 (5 Amol/L) competing peptide could compete out almost all Ugene-p binding to UNG2. To test if the NH 2 -terminal 1 to 25 amino acids of UNG2 is sufficient for binding to Ugene-p, we expressed a fusion protein with 1-25-UNG2 fused to GFP (1-25-UNG2-GFP) under the regulatory control of doxycycline. We performed this in cells already containing the 3Â FLAG epitope-tagged endogenous Ugene-p. Serial immunoprecipitation and Western blot analysis confirmed that Ugene-p bound to the (1-25-UNG2-GFP) protein (Fig. 5D) . Indeed, induction of the 1-25-UNG2-GFP decoy protein could completely outcompete and block coimmunoprecipitation of endogenous UNG2 with endogenous Ugene-p (Fig. 5D) . Therefore, the NH 2 -terminal 1 to 25 amino acids of UNG2 are sufficient in vivo for the interaction with Ugene-p.
Interestingly, despite having only two amino acid differences, Ugene-q was found not to interact with UNG2 and did not coimmunoprecipitate with it (data not shown). Introducing a single Ugene-q-specific codon change, changing tryptophan-125 to arginine was also sufficient to abolish Ugene-p binding to UNG2 (data not shown). Therefore, Trp 125 of Ugene-p is required for binding of Ugene-p to UNG2.
Ugene binding does not directly alter UNG2 enzymatic activity or localization. To examine potential functional effects of Ugene-p binding to UNG2, we performed a coimmunoprecipitation to collect UNG2 bound to Ugene-p (pulled down by antibodies against the FLAG epitope). A biochemical assay showed that UNG2 bound to Ugene-p was an active enzyme, as indicated by initiating a cascade causing cleavage of a uracil-containing oligonucleotide from the parental 21-nucleotide (nt) size down to 10 nt (Fig. 6A,  lane 2) . To ensure the activity in the Ugene-p (FLAG) immunoprecipitates derived from captured UNG2, we repeated the assay in DLD1 cells rendered UNG null by somatic cell knockout (as described in Materials and Methods; Supplementary Fig. S3 ). No activity was detected in Ugene-p immunoprecipitates from UNG null cells. Thus, we conclude that the biochemical activity detected in Ugene-p precipitates from parental DLD1 cells derives from active UNG2 bound to Ugene-p.
To examine whether binding to Ugene-p can alter UNG2 subcellular localization, we expressed V5 epitope-tagged UNG2 (UNG2-V5) in the cells conditionally expressing the 1-25-UNG2-GFP fusion protein under doxycycline regulation. Immunofluorescence against the V5 epitope showed that UNG2 was localized in the nucleus irrespective of expression of the 1-25-UNG2-GFP decoy protein ( Supplementary Fig. S2 ). Therefore, expressing a competitor for Ugene-p binding did not alter UNG2 nuclear localization.
The UNG locus encodes both a nuclear protein UNG2 and a mitochondrial isoform UNG1 that both share the same catalytic domain but are of different sizes (17) . In repeated assays, only a UNG2-sized protein was ever detected in Ugene-p immunoprecipitates (data not shown).
To further assay the effects of Ugene-p expression on UNG2 activity, we generated cells null for UNG1. This was done by Top, tests for interaction of Ugene-p and UNG2 by immunoprecipitation of UNG2 and Western detection of Ugene-p; bottom, expression of Ugene-p and UNG2 proteins. B, schematic diagram of the targeting vector for tagging endogenous Ugene-p with 3Â FLAG. Numbers above the boxes, exons; black boxes, untranslated regions (UTR ); white boxes, coding sequences. C, Western blot detection of endogenous Ugene-p and its interaction with endogenous UNG2. Ugene-p was immunoprecipitated from Ugene-p-3ÂFLAG-tagged cells using FLAG antibodies. Top, endogenous Ugene-p protein detected by Western blot (IB ) against the FLAG epitope; bottom, the presence of coimmunoprecipitated UNG2 by Western blot against UNG2. Assay of parental DLD1 cells is shown as controls.
selective knockout of the UNG1-specific exon 1 from the UNG locus. In these cells expressing UNG2 only, we again introduced the 1-25-UNG2-GFP decoy protein under doxycycline regulation. These cells were used to determine UNG2 enzymatic activity under two experimental conditions (Fig. 6C) . First, we compared UNG2 activity in cell lysates without (doxÀ) and with (dox+) induced expression of the 1-25-UNG2-GFP decoy protein (top). As shown in Fig. 5D , the highly expressed decoy protein totally abolished the interaction of Ugene-p and UNG2, but did not alter UNG2 biochemical activity in the lysates, as shown in Fig. 6C (top) . Specifically, an equal signal intensity of the 10-nt cleavage product of the uracil-containing oligonucleotides was seen in both dox+ and doxÀ conditions. Second, we compared UNG2 activity in lysates prepared from cells without and with suppression of Ugene expression by siRNA. As shown in Fig. 6B , Ugene-specific siRNA (siRNA1017) could efficiently suppress Ugene expression by >90% at 48 h after transfection. However, Ugene knockdown did not change the enzymatic activity of UNG2 as shown in Fig. 6C (bottom) . These findings were equally true whether UNG2 activity was analyzed with a 21-bp oligonucleotide containing a U-A or a U-G mispair at position 10, which, respectively, modeled uracil misincorporation into DNA and uracil arising from spontaneous deamination of cytosine. These results suggest that under the experimental condition used, changing Ugene-p expression did not alter UNG2 biochemical activity.
Discussion
We report here the identification of a novel gene, Ugene-p, the expression of which is broadly induced in many human cancer Figure 5 . Mapping of the UNG2 domain for binding to Ugene-p. A, schematic diagram of constructs expressing nested UNG2 deletions. B, HEK 293T cells were transfected with FLAG-tagged Ugene-p and a cDNA encoding either V5-tagged wild-type UNG2 or the indicated UNG2 deletion mutants. At 48 h after transfection, immunoprecipitates prepared by immunoprecipitation with FLAG antibodies were analyzed by Western blot (IB ) for UNG2 (V5) and Ugene-p (FLAG). Box, deletion of UNG2 amino acid 3-33 abolished the binding to Ugene-p. Bottom, expression of V5-tagged wild-type UNG2 and UNG2 deletion proteins in whole-cell lysates. C, cell lysates of DLD1 expressing endogenous 3Â FLAG-tagged Ugene-p were mixed with artificially synthesized competing peptides (1-25-UNG2, amounts as indicated), then immunoprecipitated with FLAG antibodies. Immunoprecipitates were analyzed by Western blot (IB ) for the presence of Ugene-p (FLAG) and for coimmunoprecipitation of UNG2 (V5). D, DLD1 cells expressing endogenous 3Â FLAG-tagged Ugene-p were transfected with pcDNA6/TR and pcDNA4-1-25-UNG2-GFP and selected by blasticidin (10 Ag/mL) and zeocin (200 Ag/mL) to derive clones conditionally expressing 1-25-UNG2-GFP fusion protein under doxycycline (dox ) regulation. These clones are designated as DLD/Ugene-p-3ÂFLAG/1-25-UNG2-GFP. The interaction of Ugene-p with either UNG2 or the 1-25-UNG2-GFP decoy protein was assayed by immunoprecipitation for Ugene-p with the FLAG antibody, followed by Western blot detection of Ugene-p, GFP, and UNG2, in cells without (doxÀ) and with (dox +) induced expression of the 1-25-UNG2-GFP decoy protein.
types. Moreover, we show the interaction of Ugene-p with UNG2, a BER enzyme. The frequent overexpression of Ugene-p in cancer suggests that this gene may participate in the cancer phenotype. A direct assay to test Ugene-p for oncogenic activity, however, revealed no transforming or focus-forming activity when tested in epithelial (HMEC) or fibroblast (WI-38, IMR-90, REF-52, NIH 3T3) cells (data not shown).
The interaction of Ugene-p with UNG2, in particular, is highly intriguing, as multiple DNA repair pathways are now recognized as targets for alteration in cancers, including inactivation of genes in the mismatch repair pathway in colon cancers (1) and inactivation of the BRCA1/2 proteins in breast cancers (18) . Despite this intriguing association, we have not yet been able to show a direct regulation of UNG2 repair activity by Ugene-p in vitro. It is likely, however, that the in vivo activity of UNG2 is more complicated than we have been able to model in in vitro assays, as UNG2 in vivo activity involves recognition of misincorporated uracil at the replication fork and involves recognition of uracils that are spontaneously generated through cytosine deamination in native chromatin, in addition to involving interactions with other members of the BER complex. The fact that immunoprecipitation of overexpressed FLAG-tagged Ugene-p pulled down only a subpopulation of total UNG2 protein (data not shown) suggests that Ugene-p could promote a specialized function of UNG2. Of note, the NH 2 terminus of UNG2, to which Ugene-p binds, has been shown to also bind to the PPM1D phosphatase that dephosphorylates Thr-6, effecting a protein modification that is suggested to play an important role in the regulation of UNG2 activity under some circumstances (19) . Further analysis of the effect of Ugene-p on UNG2 in these native contexts will be undertaken in future studies.
Genome comparisons show that Ugene-p arose as a feature of mammalian cells, in which it is highly conserved, suggesting an important role for the protein in higher organisms. It is, however, unclear from the current genome assemblies whether there are two copies of the Ugene-p on chromosome 1 or whether the chromosome 1 assembly remains in need of revision. In contrast, Ugene-q, which is unable to bind UNG2, is specific to humans and absent in other mammals. It is tempting to speculate that Ugene-q may act as a competitor of Ugene-p interactions with other proteins, but testing of this model awaits additional clarification of the functional activities of Ugene-p. Additional future study will also be needed to clarify the role of a second protein, NOSIP, that in our initial pull-down experiment was also identified as binding to Ugene-p, but that on further evaluation proved to not coprecipitate with UNG2 (data not shown).
In summary, we report Ugene-p as a novel gene commonly overexpressed in human cancers and participating in a nuclear complex with the BER gene, UNG2. 
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